Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
- Registration Number
- NCT06400537
- Lead Sponsor
- Wuhan Union Hospital, China
- Brief Summary
The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).
- Detailed Description
The pathogenic B cells of patients with SLE can produce a large amount of autoantibodies, which will form immune complexes and thereby inducing continuously expanding tissue damage and systemic inflammation. A-319 is a kind of recombinant CD19xCD3 double antibody, it can activate internal T cells to target and kill pathogenic B cells. Clinical trials of A-319 are currently underway in hematological maliganancies concerning B cell abnormality. Preclinical studies have shown the efficacy of A-319 in SLE. The aim of this study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and preliminary efficacy of A-319 in active/refractory SLE. Patients with active/refractory SLE will be invited to participate in the study, to receive A-319 intravenous infusion or subcutaneous injection and follow-up visits of up to 1 years after enrollment.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 25
- Age 18-60 years old, regardless of gender;
- Participants diagnosed with SLE according to the American College of Rheumatology (ACR) 1997 revised criteria for SLE at least 24 weeks prior to signing the informed consent form;
- Active/refractory systemic lupus erythematosus;
- Positive test results for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) immunofluorescence assay at a titer of ≥1:80; anti-dsDNA; or anti-Smith (anti-Sm);
- Receive the standardized and stable treatment for at least 30 days before the first administration of the study drug;
- Female participants tested negative for pregnancy, and participants agreed to use effective contraception throughout the trial;
- Have the ability to understand the nature of the research and voluntarily sign an informed consent form;
- Participants can communicate well with the researchers and complete all visits according to the requirements of the plan.
- Severe kidney disease;
- Participants who have central nervous system diseases caused by SLE or non-SLE disease within 8 weeks before the first administration of the study drug;
- Abnormities of main organ function at screening;
- Medical history that the researchers believe will pose risk to the safety of the participants, or will affect the safety or effectiveness analysis of the study drug;
- Active mycobacterium tuberculosis infection;
- Active hepatitis, or hepatitis B virus surface antigen positive, or hepatitis B virus core antibody positive and hepatitis B virus deoxyribonucleic acid positive, or hepatitis C virus antibody positive at screening;
- History of human immunodeficiency virus infection, or positive antibodies at screening;
- Positive syphilis spirochete antibody at screening (except false positive caused by SLE);
- Participants with chronic active infection or acute infection need systemic anti-infection treatment within 4 weeks before screening, or have superficial skin infection requiring treatment within 1 week before screening;
- Have undergone major surgery or unhealed wounds, ulcers or fractures within 4 weeks before the first administration of the study drug, or plan to perform major surgery during the study period;
- Participants diagonosed with malignant tumors within 5 years before screening;
- History of important organ transplantation or hematopoietic stem cells/or bone marrow transplantation;
- Have been vaccinated or plan to receive live vaccine or live attenuated vaccine during the research period within 4 weeks before the first administration of the study drug;
- Participated in any clinical trial within 4 weeks before the first administration of the study drug or within 5 half-lives of the study drug of the clinical trial;
- Received targeted drugs (rituximab, JAK inhibitors, etc.) at a specific time period before the first administration of the study drug;
- Received intravenous immunoglobulin, prednisone ≥100mg/d or equivalent glucocorticoid therapy within 4 weeks before the first administration of the study drug, or plasma replacement;
- Received IL-2, thalidomide, rethidone and traditional Chinese medicine within 4 weeks before the first administration of the study drug;
- Known allergies to monoclonal antibody drugs, or allergies to A-319 excipients;
- Participants with depression or suicidal thoughts;
- Women who are pregnant or breastfeeding, or women who plan to be pregnant or breastfeeding during the study period; or men whose sexual partners plan to become pregnant during the study period;
- Any reason that the researchers believe will hinder the subject's participation in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A-319 intravenous intervention A-319 A-319 will be preset with 3 escalation dose levels by intravenous infusion: dose A, dose B, dose C, total course of treatment: 4 weeks. Anticipated enrollment: 9-18 participants. A-319 subcutaneous intervention A-319 A-319 will be preset with 6 escalation dose levels by subcutaneous injection: dose A, dose B, dose C, dose D, dose E, dose F, total course of treatment: 4 weeks. Anticipated enrollment: dose A, B: 3; dose C-F: 3+N; total: 16-31 participants.
- Primary Outcome Measures
Name Time Method Safety and tolerability Within 1 year since A-319 infusion Safety and tolerability will be assessed by incidence and severity of adverse events (AEs) and serious AEs (SAEs)
- Secondary Outcome Measures
Name Time Method Pharmacokinetics of A-319 Within 1 month since A-319 infusion Concentration of A-319 in peripheral blood will be evaluated
Numbers of Participants with positive antidrug antibodies in peripheral blood Day 28 and month 3 since A-319 infusion To evaluate immunogenicity of A-319
Pharmacodynamics of A-319 Within 1 month since A-319 infusion Pharmacodynamics will be assessed by levels of lymphocyte subsets in peripheral blood
Trial Locations
- Locations (2)
Shanxi Bethune Hospital
🇨🇳Taiyuan, Shanxi, China
Wuhan Union Hospital
🇨🇳Wuhan, Hubei, China